The table below shows the number of adverse reactions and serious adverse reactions, and how many participants stopped receiving trial treatment due to adverse reactions. This includes information for adverse reactions the doctors thought were related to one of the trial drugs, or the drugs together.

Group 1 and Group 2 
(out of 45 participants) 

Acalabrutinib 80.0% (36) 
Obinutuzumab 60.0% (27) 
Venetoclax 41.7% (10) 
Rituximab 29.2% (7) 
Acalabrutinib and obinutuzumab together 42.2% (19) 
Acalabrutinib, obinutuzumab, and venetoclax together 

Group 3 and Group 4 
(out of 24 participants) 

Acalabrutinib 83.3% (20) 
Obinutuzumab 16.7% (4) 

How many participants had serious adverse reactions? 

Acalabrutinib none 
Obinutuzumab none 
Venetoclax 4.2% (1) 
Rituximab none 
Acalabrutinib and obinutuzumab together 2.2% (1) 
Acalabrutinib, obinutuzumab, and venetoclax together 4.2% (1) 

How many participants stopped receiving trial treatment due to adverse reactions? 

Acalabrutinib 4.4% (2) 
Obinutuzumab none 
Venetoclax none 
Rituximab none 
Acalabrutinib and obinutuzumab together none 
Acalabrutinib, obinutuzumab, and venetoclax together 4.2% (1) 

13 | Clinical Trial Results